Avalon Investment & Advisory’s Takeda Pharmaceutical TAK Stock Holding History

Avalon Investment & Advisory’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,141	Closed	-$247K	–	337
2021 Q4	$247K	Sell	18,141 -8,262	-31%	-$116K	0.01%	287
2021 Q3	$432K	Sell	26,403 -3,579	-12%	-$60.1K	0.01%	288
2021 Q2	$505K	Sell	29,982 -7,977	-21%	-$136K	0.01%	280
2021 Q1	$693K	Sell	37,959 -111,902	-75%	-$2.01M	0.02%	262
2020 Q4	$2.73M	Buy	149,861 +1,254	+0.8%	+$22K	0.06%	184
2020 Q3	$2.65M	Sell	148,607 -45,006	-23%	-$819K	0.06%	164
2020 Q2	$3.47M	Sell	193,613 -40,227	-17%	-$722K	0.08%	143
2020 Q1	$3.55M	Buy	233,840 +106,411	+84%	+$1.93M	0.09%	150
2019 Q4	$2.51M	Buy	+127,429	New	+$2.44M	0.05%	196
2019 Q2	–	Sell	-58,089	Closed	-$1.18M	–	346
2019 Q1	$1.18M	Buy	+58,089	New	+$1.17M	0.03%	241

Other funds holding TAK

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Avalon Investment & Advisory's TAK Position: Q1 2022 in Review

Avalon Investment & Advisory sold out of Takeda Pharmaceutical (TAK) in Q1 2022, closing a stake of 18,141 shares — an estimated $247K sold.

Avalon Investment & Advisory first reported a position in TAK in Q1 2019 and held it in 10 quarters. The position peaked at $3.55M in Q1 2020. 288 funds tracked by Wall St. Rank hold TAK as of Q1 2022.

Avalon Investment & Advisory reported no remaining Takeda Pharmaceutical position as of Q1 2022 after selling out during the quarter.
Avalon Investment & Advisory sold 18,141 Takeda Pharmaceutical shares in Q1 2022, an estimated $247K.
Avalon Investment & Advisory first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 10 quarters.
Avalon Investment & Advisory's Takeda Pharmaceutical position peaked at $3.55M in Q1 2020.
288 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2022.

Based on Avalon Investment & Advisory's 13F filing for Q1 2022, filed 17 May 2022.